Compare ECBK & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECBK | MGNX |
|---|---|---|
| Founded | 1919 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.3M | 115.8M |
| IPO Year | 2022 | 2013 |
| Metric | ECBK | MGNX |
|---|---|---|
| Price | $16.90 | $2.75 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.40 |
| AVG Volume (30 Days) | 7.2K | ★ 1.5M |
| Earning Date | 04-23-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | N/A | ★ $149,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.14 |
| P/E Ratio | $25.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.55 | $0.99 |
| 52 Week High | $20.05 | $3.50 |
| Indicator | ECBK | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 56.94 |
| Support Level | $15.86 | $1.46 |
| Resistance Level | $16.53 | $3.50 |
| Average True Range (ATR) | 0.45 | 0.24 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 13.53 | 47.65 |
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.